Description
Glizid-MV Tablet SR is a combination oral antidiabetic medicine containing Voglibose 0.2 mg, Metformin 500 mg, and Gliclazide 80 mg in a sustained-release (SR) formulation. It is designed to manage Type 2 Diabetes Mellitus by targeting multiple pathways:
-
Gliclazide stimulates insulin secretion from the pancreas.
-
Metformin improves insulin sensitivity and reduces glucose production in the liver.
-
Voglibose slows carbohydrate absorption in the intestines, preventing post-meal blood sugar spikes.
The SR formulation ensures gradual and steady release of the active ingredients for better blood glucose control.
Uses
-
Management of Type 2 Diabetes Mellitus
-
For patients needing triple-action therapy when diet, exercise, or dual therapy is insufficient
Dosage
-
Take as prescribed by your doctor
-
Usually taken once daily or as advised
-
Dose may be adjusted according to blood sugar monitoring
How to Use
-
Take orally with water
-
Preferably with meals to reduce gastrointestinal side effects
-
Swallow the tablet whole; do not crush or chew
-
Follow diet and exercise plan recommended by your doctor
Precautions
-
Not for Type 1 diabetes or diabetic ketoacidosis
-
Inform your doctor if you have kidney or liver disease
-
Monitor blood glucose regularly
-
Limit alcohol consumption
-
Use with caution during pregnancy or breastfeeding
Side Effects
Common side effects may include:
-
Hypoglycemia (mainly due to Gliclazide)
-
Nausea, vomiting, diarrhea, or abdominal discomfort (mainly due to Metformin and Voglibose)
-
Headache
-
Bloating or mild abdominal discomfort
-
Weight gain
Seek immediate medical attention if severe hypoglycemia or unusual symptoms occur.
Leave a Reply